Your Patients Can't Find Their Estradiol Patches — Here's How to Help

If your clinic has been fielding an increasing number of calls from patients who can't fill their estradiol patch prescriptions, you're not alone. The discontinuation of Alora by AbbVie, combined with broader estradiol transdermal supply constraints in 2026, has created a challenging situation for patients and the practices that serve them.

This guide provides actionable strategies for helping your patients maintain access to menopausal hormone therapy during this supply disruption.

Understanding the Current Landscape

The supply issues affecting estradiol patches in 2026 have multiple layers:

• Alora is permanently discontinued — all strengths, no expected return. Patients still holding Alora prescriptions need new prescriptions written
• Generic estradiol patches are intermittently unavailable at many retail pharmacies due to manufacturing capacity constraints and surging demand
• Not officially an FDA-listed shortage — which means many of the formal shortage mitigation protocols (e.g., extended NDC access, temporary importation) have not been triggered
• Demand continues to grow — more clinicians are prescribing MHT as updated evidence supports its use for symptomatic menopausal women, and patient awareness is at an all-time high

Immediate Steps for Your Practice

1. Identify Affected Patients Proactively

Don't wait for patients to call in distress. Run a report in your EHR to identify all patients currently prescribed:

• Alora (any strength) — these patients definitely need new prescriptions
• Generic estradiol transdermal patches — these patients may face fill difficulties
• Vivelle-Dot, Minivelle, Dotti — these patients may also be affected

Proactive outreach demonstrates patient-centered care and reduces urgent phone volume.

2. Prescribe for Maximum Flexibility

How you write the prescription can make a significant difference in whether it gets filled:

• Prescribe generically: "Estradiol transdermal system" rather than a specific brand. This gives the pharmacist maximum flexibility to fill from available stock
• Authorize substitution explicitly: Even in states with default generic substitution, noting "substitution permitted" or "may substitute therapeutically equivalent estradiol transdermal product" removes ambiguity
• Consider dose flexibility: For patients on strengths that are particularly scarce, note whether a nearby dose with patient counseling would be acceptable (e.g., two lower-strength patches if the prescribed strength is unavailable)

3. Direct Patients to Inventory Tools

Medfinder for Providers offers real-time pharmacy inventory search capabilities. You can:

• Search for estradiol patch availability by the patient's zip code during the appointment
• Send the prescription to a pharmacy confirmed to have stock, rather than the patient's usual pharmacy
• Provide patients with the link to search on their own: medfinder.com

This one step can save patients hours of calling pharmacies and dramatically reduce callback volume to your practice.

4. Establish a Shortage Response Protocol

Create a standardized workflow for your practice:

1. Patient calls: "I can't fill my estradiol patch prescription"
2. Front desk / triage: Directs patient to check Medfinder. If still unsuccessful, escalates to nursing staff
3. Nursing / clinical staff: Reviews chart. If generic patch prescribed, confirms substitution authorization. If specific brand prescribed, initiates provider review for broader Rx
4. Provider: If patches unavailable in the patient's area, prescribes alternative formulation (gel, spray, oral) with appropriate patient counseling. Documents shortage as the reason for change

Having this protocol in place prevents ad hoc decision-making and ensures consistent patient care.

Clinical Strategies for Maintaining Continuity

Tiered Substitution Approach

Consider this hierarchy when a patient's current estradiol patch is unavailable:

1. Tier 1 — Same route, different brand/generic: Switch to any available estradiol transdermal patch at the equivalent daily dose. Lowest disruption to the patient
2. Tier 2 — Climara (once-weekly patch): Different application schedule but same transdermal route. May have separate supply availability due to different manufacturing
3. Tier 3 — Topical estradiol (gel or spray): Divigel, EstroGel, or Evamist. Maintains transdermal delivery advantages. Requires daily application rather than twice weekly
4. Tier 4 — Oral estradiol: Estrace or generic. Widely available and affordable ($4-$15/month). First-pass hepatic metabolism means different risk-benefit profile, particularly regarding thromboembolic risk and triglycerides. May not be appropriate for patients with elevated thrombotic risk or hypertriglyceridemia

Bridge Prescriptions

For patients who expect patches to become available soon (e.g., pharmacy has a backorder with an estimated arrival date):

• Write a short-term (2-4 week) prescription for oral estradiol as a bridge
• Note in the chart: "Bridge therapy pending patch availability"
• Schedule or flag for follow-up when the original patch is filled

Sample Availability

If your practice receives pharmaceutical samples, check for estradiol patches. Even a few weeks' worth of samples can bridge a gap for patients in acute need. Contact your Bayer (Climara) or other patch manufacturer representative about sample availability.

Addressing Patient Concerns

Patients affected by medication shortages often experience significant anxiety. Common concerns and suggested responses:

• "Why can't anyone find my medication?" — Explain the supply/demand dynamics honestly. Validate their frustration while reassuring them that the active ingredient is available in other forms
• "Is my replacement going to work as well?" — For patch-to-patch switches, bioequivalence supports equivalent efficacy. For route changes, explain that most patients achieve good symptom control and that you'll monitor their response
• "Will this cost me more?" — Direct them to discount programs. Generic estradiol patches typically cost $25-$80/month with coupons; oral generic estradiol can be as low as $4-$15/month. Share our patient resource: How to save money on Alora in 2026
• "Should I just stop taking estrogen?" — Counsel against abrupt discontinuation. Discuss the clinical rationale for continuing therapy and work together on a plan to maintain access

Documentation Best Practices

When making supply-driven prescription changes:

• Document the specific unavailability (e.g., "Alora discontinued; generic estradiol patch unavailable at patient's pharmacy and 3 nearby pharmacies per Medfinder search")
• Note the clinical rationale for the chosen alternative
• Record the patient's understanding and agreement with the change
• Set a follow-up timeline (4-8 weeks) to reassess symptom control
• Flag for return to preferred formulation when available, if clinically appropriate

Resources for Your Practice

• Medfinder for Providers — Real-time pharmacy inventory search
• Alora shortage: What providers and prescribers need to know in 2026 — Clinical overview with dose conversion tables and therapeutic alternatives
• How to help patients save money on Alora: A provider's guide

Patient handouts to share:

• How to find Alora in stock near you (tools + tips)
• Alternatives to Alora if you can't fill your prescription
• Alora shortage update: What patients need to know in 2026